GridAI Technologies Corp.

What they do

GridAI develops software and services to optimize energy infrastructure for AI data centers and large energy users, using distributed energy resources, battery storage, on-site generation, and grid interconnections. Its platform is still in development and generates no revenue from that segment. The company also continues development of Adrulipase, a recombinant lipase enzyme for exocrine pancreatic insufficiency. The energy business operates through wholly owned subsidiary Grid AI Corp. and its AMPX subsidiaries.

Revenue drivers

• Grid AI energy software — No revenue yet; platform in development stage and commercial pipeline just being re-established through consulting-led engagements.
• Adrulipase biopharmaceutical program — Pre-commercial; ongoing development but no approved product or sales; Phase 2b bridging study missed primary endpoint.

Recent performance

For the three months ended March 31, 2026, revenue was $38,208, nearly all from the newly acquired Grid AI business. For fiscal year 2025, revenue was $36,251 with a net loss of $6.4 million and operating cash outflow of $5.7 million. Diluted EPS for 2025 was -$4.16, much improved from -$15.99 in 2024. As of March 31, 2026, total assets were $48.0 million, cash was $385,542, and shareholder equity was $23.6 million.

Strategy

Management is focused on building out the Grid AI energy optimization platform and re-establishing its commercial pipeline through consulting-led engagements and targeted business development. The company completed a share exchange on September 30, 2025 to acquire Grid AI Corp. and its AMPX subsidiaries. It is retaining Adrulipase but will pursue next steps subject to available capital and strategic priorities. The company exited non-core assets by rescinding the ImmunogenX acquisition and terminating the Sanofi Capeserod license.

Risks

• Going concern — The company depends on external funding and has substantial doubt about its ability to continue as a going concern.
• Nasdaq delisting — Received a delisting notice on April 28, 2026 and previously was non-compliant with Nasdaq listing rules.
• Minimal cash — Cash and equivalents were only $385,542 as of March 31, 2026, likely insufficient to fund near-term operations.
• Platform pre-revenue — The Grid AI energy platform has no revenue yet and commercial success is unproven.

Outlook

Management expects to continue developing Adrulipase as capital allows and to advance the Grid AI platform's commercial pipeline. The company will need substantial additional financing to fund operations and product development. The energy business, through AMPX Limited, represents the primary growth opportunity, but near-term financial stability is uncertain.